US-based biotech Cerevance is continuing an ongoing pivotal study of its Parkinson’s disease candidate despite it showing no benefit compared to placebo in a Phase II study. The biotech ...

Solengepras shows strong potential as an adjunctive therapy for Parkinson’s, offering a novel, well-tolerated option with ...

Cerebrospinal fluid (CSF) sampling demonstrated high levels of central nervous system (CNS) exposure with CVN293. Additional Cerevance Presentations at AAN 2025 The company presented a poster ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better than placebo in phase 2 when given to people with early, untreated ...

Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of neurodegenerative, psychiatric, and central nervous system-controlled ...

Takeda and venture capital group Lightstone Ventures have launched Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric ...

Additional Cerevance Presentations at AAN 2025The company presented a poster demonstrating the potential of its proprietary NETSseq platform to identify and/or validate cell-specific gene targets ...